Imperial backs Cell Medica

The commercialization and investment arm of Imperial College London, Imperial Innovations, has led a £1.95m round in Cell Medica, a cellular therapeutics company.

Investing £1.16 m, a further £0.79m came from private investors, meaning the business has now raised a total of £4.5 m in equity and convertible debt investment capital following its launch in 2007 with backing from Imperial Innovations and the Wellcome Trust.

Cell Medica is developing cell-based treatments for infectious disease and cancer, and will use the money it has raised to commercialise one of its therapies, Virus-specific Immune Reconstitution, which protects patients with weakened immune systems against cytomegalovirus (CMV) infections, which are particularly common amongst bone marrow transplant patients.